Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma

Asthma is a phenotypically heterogeneous chronic disease of the airways, characterized by either predominant eosinophilic or neutrophilic, or even mixed eosinophilic/neutrophilic inflammatory patterns. Eosinophilic inflammation can be associated with the whole spectrum of asthma severity, ranging from mild-to-moderate to severe uncontrolled disease, whereas neutrophilic inflammation occurs mostly in more severe asthma. Eosinophilic asthma includes either allergic or nonallergic phenotypes underlying immune responses mediated by T helper (Th)2 cell-derived cytokines, whilst neutrophilic asthma is mostly dependent on Th17 cell-induced mechanisms. These immune-inflammatory profiles develop as a consequence of a functional impairment of T regulatory (Treg) lymphocytes, which promotes the activation of dendritic cells directing the differentiation of distinct Th cell subsets. The recent advances in the knowledge of the cellular and molecular mechanisms underlying asthmatic inflammation are contributing to the identification of novel therapeutic targets, potentially suitable for the implementation of future improvements in antiasthma pharmacologic treatments.

[1]  M. Kool,et al.  Mode of dendritic cell activation: the decisive hand in Th2/Th17 cell differentiation. Implications in asthma severity? , 2015, Immunobiology.

[2]  R. Pawankar,et al.  The paradigm of cytokine networks in allergic airway inflammation , 2015, Current opinion in allergy and clinical immunology.

[3]  S. Wenzel,et al.  Pathobiology of severe asthma. , 2015, Annual review of pathology.

[4]  M. Humbert,et al.  Asthma: still a promising future? , 2014, European Respiratory Review.

[5]  C. Akdis,et al.  Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-β , 2014, Genes and Immunity.

[6]  D. Agrawal,et al.  Key mediators in the immunopathogenesis of allergic asthma. , 2014, International immunopharmacology.

[7]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[8]  Choon-Sik Park,et al.  Role of inflammasome activation in development and exacerbation of asthma , 2014, Asia Pacific allergy.

[9]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[10]  Hergen Spits,et al.  Innate lymphoid cells in inflammation and immunity. , 2014, Immunity.

[11]  H. Kita,et al.  Enhanced innate type 2 immune response in peripheral blood from patients with asthma. , 2014, The Journal of allergy and clinical immunology.

[12]  A. Lindén,et al.  Interleukin-17 cytokine signalling in patients with asthma , 2014, European Respiratory Journal.

[13]  D. Sheppard,et al.  The cell biology of asthma , 2014, The Journal of cell biology.

[14]  A. Rossi,et al.  Eosinophils in the Lung – Modulating Apoptosis and Efferocytosis in Airway Inflammation , 2014, Front. Immunol..

[15]  M. Lamkanfi,et al.  Inflammasomes in respiratory disease: from bench to bedside. , 2014, Chest.

[16]  P. Klenerman,et al.  Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells☆ , 2014, The Journal of allergy and clinical immunology.

[17]  A. McKenzie,et al.  Faculty Opinions recommendation of Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. , 2014 .

[18]  J. D. Di Santo,et al.  Gata3 drives development of RORγt+ group 3 innate lymphoid cells , 2014, The Journal of experimental medicine.

[19]  G. Shi,et al.  [Innate lymphoid cells and asthma]. , 2014, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[20]  John F Alcorn,et al.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection , 2014, Expert review of respiratory medicine.

[21]  H. Hammad,et al.  The immunology of asthma , 2014, Nature Immunology.

[22]  P. Ilmarinen,et al.  Eosinophil apoptosis as a therapeutic target in allergic asthma. , 2014, Basic & clinical pharmacology & toxicology.

[23]  R. Peebles,et al.  Th17-mediated inflammation in asthma. , 2013, Current opinion in immunology.

[24]  S. Wenzel Complex phenotypes in asthma: current definitions. , 2013, Pulmonary pharmacology & therapeutics.

[25]  E. Kerwin,et al.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. , 2013, American journal of respiratory and critical care medicine.

[26]  S. Phipps,et al.  Elevated expression of the NLRP3 inflammasome in neutrophilic asthma , 2013, European Respiratory Journal.

[27]  S. Pflugfelder,et al.  Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation , 2013, Mucosal Immunology.

[28]  K. Bracke,et al.  Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma , 2013, Nature Medicine.

[29]  A. Vatrella,et al.  Update on Anticytokine Treatment for Asthma , 2013, BioMed research international.

[30]  A. McKenzie,et al.  Innate lymphoid cells — how did we miss them? , 2013, Nature Reviews Immunology.

[31]  Q. Hamid,et al.  T helper 17 cells in airway diseases: from laboratory bench to bedside. , 2013, Chest.

[32]  M. Rothenberg,et al.  Targeting eosinophils in allergy, inflammation and beyond , 2013, Nature Reviews Drug Discovery.

[33]  M. Contoli,et al.  Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. , 2012, The Journal of allergy and clinical immunology.

[34]  A. Vatrella,et al.  The potential of biologics for the treatment of asthma , 2012, Nature Reviews Drug Discovery.

[35]  James J. Lee,et al.  The expanding role(s) of eosinophils in health and disease. , 2012, Blood.

[36]  D. Ojcius,et al.  Alarmins, inflammasomes and immunity. , 2012, Biomedical journal.

[37]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[38]  N. Thomson,et al.  Smoking and asthma: dangerous liaisons , 2012, European Respiratory Journal.

[39]  R. Kolbeck,et al.  Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  H. Chi,et al.  Regulation of TH17 cell differentiation by innate immune signals , 2012, Cellular and Molecular Immunology.

[41]  H. Kita,et al.  IL-33–Responsive Lineage−CD25+CD44hi Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the Lungs , 2012, The Journal of Immunology.

[42]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[43]  J. Alcorn,et al.  T(H)17 cells in asthma and inflammation. , 2011, Biochimica et biophysica acta.

[44]  Hergen Spits,et al.  Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161 , 2011, Nature Immunology.

[45]  L. Cosmi,et al.  Th17 cells: new players in asthma pathogenesis , 2011, Allergy.

[46]  M. Wills-Karp,et al.  The Potential Role of Interleukin-17 in Severe Asthma , 2011, Current allergy and asthma reports.

[47]  Ya-Jen Chang,et al.  Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity , 2011, Nature Immunology.

[48]  A. Gounni,et al.  The Molecular Mechanisms of Glucocorticoids-Mediated Neutrophil Survival , 2011, Current drug targets.

[49]  P. Foster,et al.  New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma , 2011, Current opinion in allergy and clinical immunology.

[50]  C. Lloyd,et al.  Functions of T cells in asthma: more than just TH2 cells , 2010, Nature Reviews Immunology.

[51]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.

[52]  Y. Park,et al.  Eosinophil Survival and Apoptosis in Health and Disease , 2010, Allergy, asthma & immunology research.

[53]  W. Henderson,et al.  An update on the role of leukotrienes in asthma , 2010, Current opinion in allergy and clinical immunology.

[54]  C. Anandan,et al.  Is the prevalence of asthma declining? Systematic review of epidemiological studies , 2010, Allergy.

[55]  D. Metzger,et al.  Emerging Roles of T Helper Subsets in the Pathogenesis of Asthma , 2010, Immunological investigations.

[56]  S. Willsie Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[57]  P. Howarth,et al.  A new look at the pathogenesis of asthma , 2009, Clinical science.

[58]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[59]  C. Bachert,et al.  Decreased FOXP3 protein expression in patients with asthma , 2009, Allergy.

[60]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[61]  C. Lemière,et al.  T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. , 2009, The Journal of allergy and clinical immunology.

[62]  C. Lloyd Dust mites' dirty dealings in the lung , 2009, Nature Medicine.

[63]  H. Hammad,et al.  House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells , 2009, Nature Medicine.

[64]  Y. Nakanishi,et al.  Frequency of Foxp3+CD4+CD25+ T cells is associated with the phenotypes of allergic asthma , 2009, Respirology.

[65]  T. Mcclanahan,et al.  The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo , 2009, Nature Immunology.

[66]  J. Fahy,et al.  Acute exacerbations of asthma: epidemiology, biology and the exacerbation‐prone phenotype , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[67]  N. Schmitz,et al.  CD40–CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells , 2009, Proceedings of the National Academy of Sciences.

[68]  P. Barnes,et al.  The cytokine network in asthma and chronic obstructive pulmonary disease. , 2008, The Journal of clinical investigation.

[69]  G. Anderson,et al.  Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease , 2008, The Lancet.

[70]  G. Kaiko,et al.  Immunological decision‐making: how does the immune system decide to mount a helper T‐cell response? , 2008, Immunology.

[71]  W. Henderson,et al.  Mechanisms of disease: Leukotrienes , 2007 .

[72]  U. Wahn,et al.  T-cell co-stimulatory molecules: their role in allergic immune reactions , 2007, European Respiratory Journal.

[73]  N. Kadowaki Dendritic Cells-A Conductor of T Cell Differentiation. , 2007, Allergology international : official journal of the Japanese Society of Allergology.

[74]  H. Issever,et al.  Serum amyloid A (SAA) in induced sputum of asthmatics: a new look to an old marker. , 2006, International immunopharmacology.

[75]  Stephen T Holgate,et al.  Role of deficient type III interferon-λ production in asthma exacerbations , 2006, Nature Medicine.

[76]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[77]  I. Pavord,et al.  Evidence of a role of tumor necrosis factor alpha in refractory asthma. , 2006, The New England journal of medicine.

[78]  B. Thiers Evidence of a Role of Tumor Necrosis Factor α in Refractory Asthma , 2006 .

[79]  N. Thomson,et al.  Asthma and cigarette smoking , 2004, European Respiratory Journal.

[80]  S. Orkin,et al.  A Critical Role for Eosinophils in Allergic Airways Remodeling , 2004, Science.

[81]  D. Fabian,et al.  The global burden of asthma: executive summary of the GINA Dissemination Committee Report , 2004, Allergy.

[82]  A. Kay,et al.  The role of T lymphocytes in the pathogenesis of asthma. , 2003, The Journal of allergy and clinical immunology.

[83]  M. Lindsay,et al.  Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. , 2002, Life sciences.

[84]  Eugene Y. Kim,et al.  Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4 , 2002, Nature Medicine.

[85]  P. Bozza,et al.  The cellular biology of eosinophil eicosanoid formation and function. , 2002, The Journal of allergy and clinical immunology.

[86]  E. Moilanen,et al.  Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. , 2000, European journal of pharmacology.